Advancing Precision Medicine in High-Risk Breast Cancer: BRCA Mutations, Triple-Negative, and HR+/HER2– Subtypes - Episode 3
BRCA Testing in Early-Stage and Metastatic Breast Cancer
Panelists discuss their approach to BRCA testing in early-stage versus metastatic breast cancer patients, highlighting the 2024 American Society of Clinical Oncology (ASCO) guidelines for germline testing and exploring which patients are not tested for BRCA, as well as how they differentiate between germline and somatic testing approaches.
Video content above is prompted by the following:
- Dr. Shatsky asks Dr. Degen: Please discuss how you approach BRCA testing in early stage versus metastatic breast cancer patients. Please also briefly highlight the ASCO guidelines that were recently updated in 2024 for germline testing in patients with breast cancer (https://ascopubs.org/doi/full/10.1200/JCO.23.02225).
- What patients are you not testing for BRCA?
- How do you differentiate your approach for germline versus somatic testing?
Related Content:
